These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34141773)

  • 21. Atezolizumab, a PD-L1 Inhibitor: An Association of Bleeding Gastric Ulcer With Its Use.
    Bapatla A; Tariq T; Haider MB; Mohamad B
    Cureus; 2021 Jun; 13(6):e15637. PubMed ID: 34150414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature.
    Singh B; Kaur P; Maroules M
    J Investig Med High Impact Case Rep; 2021; 9():2324709621992207. PubMed ID: 33787380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report.
    Uchida K; Ozono Y; Uchiyama N; Hatada H; Nakamura K; Komaki Y; Iwakiri H; Hasuike S; Nagata K; Sato Y; Kawakami H
    Medicine (Baltimore); 2022 Sep; 101(35):e30486. PubMed ID: 36107543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with
    Reck M; Shankar G; Lee A; Coleman S; McCleland M; Papadimitrakopoulou VA; Socinski MA; Sandler A
    Expert Rev Respir Med; 2020 Feb; 14(2):125-136. PubMed ID: 31829747
    [No Abstract]   [Full Text] [Related]  

  • 26. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
    BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
    Rini BI; Powles T; Atkins MB; Escudier B; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Lee JL; Hawkins R; Ravaud A; Alekseev B; Staehler M; Uemura M; De Giorgi U; Mellado B; Porta C; Melichar B; Gurney H; Bedke J; Choueiri TK; Parnis F; Khaznadar T; Thobhani A; Li S; Piault-Louis E; Frantz G; Huseni M; Schiff C; Green MC; Motzer RJ;
    Lancet; 2019 Jun; 393(10189):2404-2415. PubMed ID: 31079938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events.
    Hayashi H; Sawada K; Hasebe T; Nakajima S; Sawada J; Takiyama Y; Takiyama Y; Okumura T; Fujiya M
    Intern Med; 2022 Dec; 61(23):3497-3502. PubMed ID: 35491133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
    Seetharamu N; Preeshagul IR; Sullivan KM
    Lung Cancer (Auckl); 2017; 8():67-78. PubMed ID: 28761384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma.
    Iwasaki S; Hidaka H; Uojima H; Hashimura M; Nabeta T; Sanoyama I; Wada N; Kubota K; Nakazawa T; Shibuya A; Koizumi W
    Clin J Gastroenterol; 2021 Aug; 14(4):1233-1239. PubMed ID: 34024039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
    Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
    BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atezolizumab-induced encephalitis with subdural hemorrhage and subarachnoid hemorrhage in a patient with hepatocellular carcinoma.
    Chao KH; Tseng TC
    J Formos Med Assoc; 2023 Nov; 122(11):1208-1212. PubMed ID: 37567840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
    Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
    PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two Cases of Atezolizumab-Induced Hypophysitis.
    Kanie K; Iguchi G; Bando H; Fujita Y; Odake Y; Yoshida K; Matsumoto R; Fukuoka H; Ogawa W; Takahashi Y
    J Endocr Soc; 2018 Jan; 2(1):91-95. PubMed ID: 29362727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atezolizumab-induced bilateral anterior uveitis: A case report.
    Mito T; Takeda S; Motono N; Sasaki H
    Am J Ophthalmol Case Rep; 2021 Dec; 24():101205. PubMed ID: 34585023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series.
    Aoki H; Matsumoto N; Takahashi H; Honda M; Kaneko T; Arima S; Ishii T; Mizutani T; Masuzaki R; Nirei K; Yamagami H; Ogawa M; Kanda T; Moriyama M; Miura K
    Anticancer Res; 2021 Dec; 41(12):6225-6230. PubMed ID: 34848477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma.
    Thakolwiboon S; Karukote A; Wilms H
    Cureus; 2019 Jun; 11(6):e5002. PubMed ID: 31497433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports.
    Al Zahrani A; Alfakeeh A
    J Med Case Rep; 2021 Mar; 15(1):132. PubMed ID: 33722275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Case of Immune-Related Aseptic Meningitis during Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma.
    Kawanaka H; Tajiri K; Muraishi N; Murayama A; Nukui T; Yasuda I
    Case Rep Gastroenterol; 2024; 18(1):8-13. PubMed ID: 38188593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.